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RAPID COMMUNICATION
A Common Genetic Variation in the 3'-Untranslated Region of the
Prothrombin Gene Is Associated With Elevated Plasma Prothrombin Levels
and an Increase in Venous Thrombosis
By Swibertus R Poort, Fnts R Rosendaal, Bieter H Reitsma, and Rogier M. Bertina
We have examined the prothrombin gene äs a candidate
gene for venous thrombosis in selected patients with a docu-
mented familial history of venous thrombophilia All the ex-
ons and the 5'- and 3'-UT region of the prothrombin gene
were analyzed by polymerase chain reaction and direct se-
quencing in 28 probands Except for known polymorphic
sites, no deviations were found in the coding regions and
the 5'-UT region. Only one nucleotide change (a G to A tran-
sition) at position 20210 was identified in the sequence of
the 3'-UT region Eighteen percent of the patients had the
20210 AG genotype, äs compared with 1% of a group of
healthy controls (100 subjects) In a population-based case-
DEEP-VEIN THROMBOSIS is a common disease, withan annual mcidence in the general population of ap
proximately l per l ,000 ' Risk factors include both heredi-
tary and acquired conditions ^ Generally, a tendency toward
venous thrombosis could anse from hyperactive coagulation
pathways, hypoactive anticoagulant mechamsms, or hypoac-
tive fibnnolysis " Mutations in genes that encode protems in
these pathways play an important role in the predisposition
to venous thrombosis Λ Vanant alleles of the genes encoding
protein C,1 protein S,46 antithrombin,7 and fibnnogen8 have
been shown to be relatively strong, but uncommon nsk fac-
tors for thrombosis 9 Genetic analysis of these genes showed
a large heterogeneity of mutations '8 More recently, a poor
anticoagulant response of plasma to activated protein C
(APC)10" due to the presence of a mutant factor V mole-
cule1- (factor V Leiden) was discovered and is äs yet the
most common hereditary nsk factor foi thrombosis known
Recently, some support was obtamed for the hypothesis that
the clustenng ot thrombosis in famihes is due to epistatic
effects 2 Studies in selected famihes with venous thrombosis
indicated that the piesence of mutations in two genes may
increase the penetrance of the thrombotic disease π ^
The discovery of genetic nsk factors tor thrombosis came
after the identincation ot famihes in whom the thrombophilia
segregated with an abnormal result in a plasma lest (protein
C, protein S, antithrombin, and APC resistance) '"""' 2 I
However, despite the ever growing insight mto the processes
of coagulation and hbrinolysis, the underlymg cause of many
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control study, the 20210 A allele was identified äs a common
allele (allele frequency, 1 2%; 95% confidence interval, 0.5%
to 1.8%), which increased the risk of venous thrombosis al-
most threefold (odds ratio, 2 8; 95% confidence interval, 1.4
to 5.6) The risk of thrombosis increased for all ages and
both sexes An association was found between the presence
of the 20210 A allele and elevated prothrombin levels. Most
individuals (87%) with the 20210 A allele are in the highest
quartile of plasma prothrombin levels (>1.15 U/mL). Ele-
vated prothrombin itself also was found to be a risk factor
for venous thrombosis
© 7996 by The American Society of Hematology
inhented thrombotic events remains unsolved New technol-
ogies for genetic analysis of thrombophilic famihes offer the
opportunity to use a direct genetic strategy for Identification
of other genetic defects involved in inheritable thrombophi-
1 "* ")">ha - -
We investigated the prothrombin gene äs a candidate gene
for venous thrombosis Prothrombin is the precursor of the
senne protease thrombin, a key enzyme m the processes
of hemostasis and thrombosis, that exhibits procoagulant,
anticoagulant, and antifibnnolytic activities 21" Prothrombin
is encoded by a 21 -kb-long gene26 locahzed on chromosome
L l, posifon 11 p 11 -q 12 27 The prothrombin gene is organized
in 14 exons, separated by 13 introns with the 5' upstream
untranslated (UT) region and the 3' UT region,2·6 which may
play regulatory loles in gene expression
The aim of the present study was to perform an analysis
of the prothrombin genes of selected subjects with a history
of venous thrombophilia usmg polymerase chain reaction
(PCR) and direct sequencmg of the coding regions and their
flanking sphce junctions and the 5'- and 3'-UT regions One
genetic Variation in the 3'-UT region of the prothrombin
gene, a G to A transition at nucleotide position 20210, was
found in 18% of selected patients with a personal and family
history of venous thrombosis, m 6 2% of unselected consec-
utive patients with a first, objectively confirmed episode of
deep-vem thrombosis, and in 2 3% of healthy control sub-
jects Camers of the 20210 A allele have higher plasma
prothrombin levels than controls with the normal 20210 GG
genotype and have a 2 8-fold increased risk of venous throm-
bosis
MATERIALS AND METHODS
Subjetts In a previous study, we collected detailed Information
on the occurrence of venous thrombo embohc events m the famihes
of l Π probands with a personal and family history of venous throm-
bophilia IK From these, we randomly selected 28 famihes usmg the
following cntena (1) apart from the probapd, there should be at
least two symptomatic (pieferentially first degree) relatives, and (2)
m probands and symptomatic relatives, deficiencies of protein C,
protein S, antithrombin, or plasmmogen or dysfibnnogenemia were
excluded On average, each proband had 2 4 (ränge, l to 6) symp
tomatic first degree relatives and l 8 (ränge, 0 to 5) symptomatic
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second degree relatives All probands and fatruly members gave
their mformed consent for the study of unexplamed famihal throm-
bophiha It was recently estabhshed by DNA analysis that, m this
panel of probands, the frequency of the factor V Leiden mutation,12
which is associated with a poor anticoagulant response to APC,10 is
40%
The second group of patients came from a population-based case
control study on venous thrombosis, the Leiden Thrombophiha
Study (LETS) " Bnefly, patients were selected from the Computer
files of the Anticoagulation Clmics m Leiden, Amsterdam, and Rot
terdam In the Netherlands, Anticoagulation Clmics momtor couma
rm treatment m virtually all patients with venous thrombosis m a
deflned geographic area29 30 Included are 474 unselected and consec-
utive outpatients younger than 70 years of age who were referred
for anticoagulant treatment because of a first, objectively diagnosed
episode of deep vem thrombosis The median time between the oc-
currence of the deep-vem thrombosis and blood collection was 19
months (ränge, 6 to 68 months) Nmety-one percent of the ehgible
patients were willmg to take part m the study The thrombotic pa
tients were asked to find their own healthy control subject accordmg
to predefined cntena '' This resulted m 474 population control sub-
jects matched for age and sex The mean age for patients and controls
was 47 years (ränge, 16 to 70 years for patients, ränge, 16 to 73
years for controls) and the male/female ratio among patients and
controls ahke was 3/4 ''
Blood collection and labomtory analysis Blood was collected
m tubes contammg 0 106 mmol/L tnsodium citrate Plasmas were
prepared by centnfugation for 10 minutes at 2,000g at room tempera-
ture and stored at —70°C m l 5 mL ahquots High molecular weight
DNA was extracted from the white blood cell fraction usmg Standard
methods
Prothrombin activity was measured with a chromogemc method
usmg S-2238 äs Substrate and Echis cannatus venom äs activator 31
Prothrombin antigen was determmed usmg a Laurell electroimmu-
noassay31 Protein C activity was measured with Coamate protem C
(Chromogemx, Molndal, Sweden) An amidolytic hepann cofactor
assay (Chromogemx) was used for antithrombm activity measure-
ments Total protem S antigen was determmed by polyclonal en
zyme linked immunosorbent assay (ELISA)32 The results are ex
pressed m units per mühliter, in which l U refers to the activity or
antigen present m l mL of pooled normal plasma
For the Identification of a geneüc abnormahty (or abnormahties)
in the prothrombm gene in DNA from 28 probands with a family
history of deep venous thrombosis, we used the PCR followed by
direct sequencing 33 We compared these sequences with those of 5
healthy control mdividuals Genomic DNA was specifically amph-
fied for the 14 exons with their flanking regions and for the 5'- and
3' UT regions of the prothrombm gene usmg PCR 34 The pnmers
used m the PCR were denved from the sequence of the gene26 and
are identical to those used m a previous study 33 The fragments
obtamed by PCR were punfied on 1% ultralow meltmg temperature
agarose gel The segment of the gel contammg the amphfied frag-
ment was excised and sequenced with the appropnate pnmers usmg
the dideoxynucleotide chain termmation method35 Sequencing reac-
tions were electrophoresed on 40-cm-long 8% polyacrylamide gels
The gels were dned on Whatman 3 mm paper (Whatman, Maidstone,
UK) and exposed to an χ ray film Genetic abnormahties identified
by sequencing were confirmed by restnction enzyme digestion of
amplified gene fragments When the abnormahty did not create or
abohsh a restnction site, such a site was created by introducmg a
nucleotide Substitution with a mutant ohgonucleotide dunng ampli-
fication 36 The mutant ohgonucleotide was designed with a nucleo
tide Substitution close to the 3' end, such that the combmation of
the nucleotide Substitution and the genetic abnormahty created a
new restnction enzyme cleavage site Sequence vanations m the
prothrombm gene known äs neutral polymorphic sites were identified
on the basis of previous pubhshed data,26 37 but are beyond the scope
of this study
Genetic analysis of the FV Leiden mutation (1691 G -> A) was
performed äs previously descnbed I2
Statistical analysis Odds ratios (ORs) were calculated äs a mea
sure of relative nsk in the Standard unmatched fashion A 95%
confidence interval (CI) was constructed accordmg to Woolf3S Gen-
erally, the OR estimates the nsk of thrombosis when a nsk factor
is present relative to the reference category
For nsk factor analysis concerning plasma prothrombm values,
48 patients usmg oral anticoagulant therapy were excluded from the
LETS group To assess a dose response relation, we stratified the
prothrombm values of both patients and controls mto quartlies and
calculated the ORs for the three higher levels relative to the lowest
reference level Adjustment for current oral contraceptive use (yes/
no), body mass mdex (m kilograms per square meter), menopause
(yes/no), smokmg (yes/no), age, and sex was performed by uncondi
tional logistic regression Effect modification was assessed by strat
ified analysis and logistic regression with interaction terms
Materials Deoxynucleotides, dideoxynucleotides, and bovine
serum albumm were purchased from Pharmacia (Uppsala, Sweden)
(<*35-S) dATP (>1,000 Ci/mmol) was obtamed from Amersham In-
ternational (Amersham, UK) Klenow DNA polymerase was from
Boehnnger Mannheim (Mannheim, Germany) Taq DNA polymer-
ase (Amphtaq) was purchased from Perkm Eimer Cetus (Norwalk,
CT) The chromogemc Substrate S-2238 was obtamed from Chromo
gemx (Molndal, Sweden) The Echis cannatus venom was obtamed
from Sigma (Sigma Chemical, St Louis) Restnction enzymes were
obtamed from New England Biolabs (Beverly, MA) Oligonucleo-
tides were synthesized on a Cyclone DNA Synthesizer (Millipore,
Bedford, CT) All other chemicals were of analytical grade from
Merck (Darmstadt, Germany)
RESULTS
Our strategy for the identification of sequence vanations
m the prothrombm gene was to amplify and sequence the
exons and their sphce junctions and the 5'- and 3'-UT re-
gions of the gene These regions contain the most likely sites
for mutations or polymorphisms that would affect transcrip-
tion or translation or the stabihty of the translated product
The PCR products amphfied from genomic DNA of the 28
probands and 5 healthy controls were sequenced äs reported
previously 33 Except for sequence vanations known äs neu
tral polymorphisms,2637 no nucleotide change was found m
the 14 exons and the 5'-UT region of the prothrombm gene
Only one heterozygous nucleotide transition (G to A) at
Position 20210, the last nucleotide of the 3'-UT region,26
was found m DNA of 5 of the 28 probands (18%), but not
in DNA of the 5 healthy control mdividuals (Fig 1) The
presence of this sequence vanation was confirmed with re-
stnction enzyme analysis usmg one mutagenic pnmer (Fig
2) In an extended analysis of 100 healthy subjects, the het-
erozygous state (20210 AG) was detected in 1% Homozy-
gous (20210 A A) camers were absent
Figure 3 shows the pedigree of the family of one of the
five thrombophilic patients carrymg the vanant prothrombm
allele Both the parents of the proband are heterozygous
for the 20210 A allele, whereas her sister is homozygous
Interestmgly, both the vanant prothrombm allele and the
factor V Leiden allele segregate in this pedigree All mdivid-
uals that expenenced a thrombotic event (or events) (II, l,
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Fig 1. Direct sequencing of the G -> A transition at Position 20210
in the prothrombin gene of a proband with venous thrombosis. The
figure shows part of the nucleotide sequence (nt 20198-20229) in one
orientation (5' to 3') of the 3'-UT region. The nucleotide differences
are indicated by arrows. The sequence of the prothrombin genes of
one proband is shown in track 2, and the sequence of the genes of
a control subject is shown in track 1.
III, l; III, 2) carry both genetic defects, whereas all carriers
of a single defect are still Symptom free.
The high frequency (18%) of the 20210 A allele among
patients with thrombophilia is probably affected by selection.
To study the relevance of the 20210 A allele in the popula-
tion, we undertook the analysis of a population-based pa-
tient-control study (LETS)."
The prevalence of carriers of the 20210 A allele among
healthy control subjects in the LETS was 2.3%, which corre-
sponds to an allele frequency of 1.2% (95% CI, 0.5% to
1.8%). Table l shows a higher prevalence of the 20210 AG
genotype among patients (6.2%) than among control subjects
(2.3%). Homozygous AA carriers were not found (expected
prevalence, 0.014%). The relative risk for thrombosis associ-
ated with the 20210 A allele was 2.8 (95% CI, 1.4 to 5.6).
This association persisted when controlling for age, sex, cur-
rent pill use, body mass index, menopause, and smoking.
The 20210 A allele was associated with an increased risk
for thrombosis both in men and women. We also found that
the 20210 A allele increased the risk for all age groups.
The increased risk (2.8) associated with the 20210 A allele
was not the result of overrepresentation of other risk factors,
such äs APC resistance (factor V Leiden); a deficiency of
protein C, protein S, or antithrombin; or the presence of
lupus anticoagulants. After excluding all these subjects (n =
141), we found an unmatched OR for thrombosis of 2.7
(95% CI, 1.3 to5.6).
Individuais with the normal 20210 GG genotype had a
mean prothrombin level of 1.05 U/mL (n = 860; SD, 0.15;
ränge, 0.55 to 1.56), whereas individuals with the 20210 AG
genotype had a significantly higher mean prothrombin level
of 1.32 U/mL (n = 40; SD, 0.18; ränge, 0.95 to 1.78; P <
.001). There was no notable difference in prothrombin levels
between patients and control subjects within each of the two
genotypic groups. The mean levels (in units per milliliter)
of protein C, total protein S, and antithrombin did not differ
between the 20210 GG and 20210 AG genotype (1.03, 1.04,
and 0.99 v 1.02, 1.03, and 0.98, respectively).
To assess to what extent an increased prothrombin level
in itself is a risk factor for venous thrombosis, we stratified
the prothrombin levels of patients and control subjects into
quartiles (Table 2). The OR increased with increasing pro-
thrombin levels: subjects with a prothrombin level of greater
than 1.15 U/mL had a 2.1-fold higher risk than those in the
reference category (<0.95 U/mL). The high-risk stratum of
greater than 1.15 U prothrombin/mL comprised no less than
31% of the patients and 20% of the control subjects.
Table 3 shows the distribution of the 20210 genotypes
M 1 2 3 4 5 6 7
34'
32^
Fig 2. Strategy for direct detection of the 20210 A allele in the
prothrombin gene. A 345-bp fragment from exon 14 and the 3'-UT
region of the prothrombin gene was amplified by PCR using the
primers 5'-TCTAGAAACAGTTGCCTGGC-3' (pr 93-787, nucleotides
19889-19908)2636 and a mutagenic primer 5'-ATAGCACTGGGAGCA-
TTGAA*GC-3' (pr 95-315, nucleotides 20233-20212),26 äs described in
the Materials and Methods. The nucleotide with an asterisk in the
mutagenic primer is not present in the normal sequence. A new
H/ndlll site (-A/AGCTT-) is introduced in the amplified fragments from
the less-frequent allele (A2:AAG) yielding two fragments (322 bp and
23 pb in length) after enzyme digestion (lane 6). The more-frequent
allele (A,:GAG) lacks the restriction site and therefore generates only
a 345-bp fragment by PCR-H/ndlll digestion (lanes 1 through 5 and
7). Abbreviation: M, marker
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Fig 3. Pedigree of a family in whom both the 20210 G/A sequence Variation in the prothrombin gene and the FV Leiden mutation (1691 G/
A) are segregating. Thrombotic Symptoms are indicated by a dotted upper left quartile of the Symbols; heterozygosity for the FV Leiden
mutation is indicated by a hatched upper right quartile of the Symbols; the presence of the 20210 AG genotype in the prothrombin gene is
indicated by a solid Iower right quartile of the Symbols; and the presence of the 20210 AA genotype in the prothrombin gene is indicated by
a solid Iower left and right quartile of the symbols. Individuais tested for the 20210 G/A sequence Variation in the prothrombin gene and the
FV Leiden mutation are indicated by a dot to the left of the symbol. The arrow denotes the proposita; individuals indicated by a slash through
the symbol are deceased.
over the different categories of prothrombin activity. Both
in patients and control subjects, around 87% of the individu-
als with the 20210 AG genotype were in the highest category
of prothrombin activity (>1.15 U/mL), whereas less notable
differences were observed in individuals with the normal
20210 GG genotype.
DISCUSSION
Our study shows that a novel sequence Variation in the
prothrombin gene (nt 20210 G—>A) is a moderate risk factor
for venous thrombosis (OR, 2.8; 95% CI, 1.4 to 5.6). The
further observations that the 20210 A allele is associated
with elevated prothrombin levels, that carriers of this allele
have significantly higher prothrombin levels than noncarri-
ers, and that elevated plasma prothrombin itself is also a risk
factor for thrombosis suggest that the 20210 A allele acts
through the elevated prothrombin levels.
In the LETS, the 20210 A allele was found in 6.3% of
consecutive unselected patients with a first episode of deep
vein thrombosis, indicating that the 20210 A allele is a rela-
tively common risk factor for venous thrombosis. As ex-
pected, a much higher prevalence of 20210 A carriers was
found in a group of selected patients with familial venous
thrombosis (18%). In 60% of the 20210 A carriers, the 20210
A allele was the only genetic abnormality found, whereas
in 40%, the FV Leiden mutation (R506Q)12 was also present.
The prevalence of carriers of the 20210 A allele among
Table 1. Frequencies and Thrombotic Risk for the 20210 G/A
Genotypes in the Prothrombin Gene
Table 2. Thrombosis Risk for Plasma Prothrombin Levels
Genotype
(nt 20210)
GG
AG
AA
No. of Patients
442 (93.8)
29 (6.2)
—
No. of Controls
463(97.7) 1.0t
11 (2.3) 2.8
—
95% CI
1.4-5.6
* Adjustment for age and sex, current pill use (yes/no), body mass
index, in menopause (yes/no) and smoking (yes/no) did not affect
these results.
t Reference category.
Prothrombin
Activity
(U/mL)
<0.95
0.95-1.04
1.05-1.15
>1.15
No. of
Patients*
(n = 426) (%)
85 (20)
107 (25)
102 (24)
132 (31)
No. of
Controls
(n = 474) (%)
134 (28)
125 (26)
118 (25)
97 (20)
Total No.
(n = 900)
(%)
219 (24)
232 (26)
220 (2'4)
229 (25)
ORt
1.0Φ
1.3
1.4
2.1
95% CI
0.9-2.0
0.9-2.0
1.5-3.1
* Patients on oral anticoagulant treatment are excluded (n = 48).
t Test for trend, P < .001.
φ Reference category.
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Table 3. Number of Individuais With the 20210 GG or AG Genotype
for Four Categories of Prothrombin Activity
Prothrombin Activity
<0.95 0.95-1.04 1.05-1.15
Patients* (n = 424)
20210 AG
2010 GG
Control (n = 474)
20210 AG
20210 GG
Total (n = 898)
20210 AG
20210 GG
0
85 (21)
0
134 (29)
0
219 (25)
1 (3)
105 (26)
0
125 (27)
1 (3)
230 (27)
2 (7)
99 (25)
2(18)
116(25)
4(10)
215 (25)
24 (90)
108 (28)
9(82)
88(19)
33 (87)
196 (23)
Values are the number of individuals with percentages in parenthe-
ses.
* Patients on oral anticoagulant treatment are excluded (n = 48).
controls was about 2.3%, corresponding to an allele fre-
quency of 1.2% (95% CI, 0.5% to 1.8%). This is about
eightfold higher than for protein C deficiency (0.3%)39·40 but
about twofold less frequent than the so far most common
genetic risk factor for venous thrombosis, the factor V
Leiden mutation, which is associated with APC resistance
(3% to 5%).9'"
The 20210 A allele was not only found to be a risk factor
for thrombosis but also to be associated with elevated pro-
thrombin levels. Interestingly, elevated prothrombin levels
were also a risk factor for thrombosis (Table 2). Thus, the
prothrombin level may be considered äs an effector, sug-
gesting also that other factors than the 20210 A allele can
be responsible for high prothrombin levels. How elevated
prothrombin levels may stimulate the formation of venous
thrombi is still unclear. They may lead to an imbalance
between the procoagulant, anticoagulant, and fibrinolytic
System. For instance, when higher concentrations of pro-
thrombin would lead to increased rates of thrombin genera-
tion, this might result in excessive growth of fibrin clots.
This study does not show the mechanism(s) by which the
20210 A allele of the prothrombin gene may contribute to
higher prothrombin levels. The association found for these
two variables (Table 3) and the location of 20210 G to A
transition in the 3'-UT region of the prothrombin gene may
indicate a relatively higher translation efficiency or higher
stability of the transcribed mRNA. The G/A sequence Varia-
tion is located at the last position of the 3'-UT26 at or near
the cleavage site in the mRNA precursor to which poly A
is added. Three conserved sequences in mRNA precursors,
located in the vicinity of this site, are required for cleavage
and polyadenylation: the AAUAAA sequence, the nucleotide
to which poly A is added, and the region downstream of this
nucleotide.41·42 Generally, the nucleotide to which poly A is
added is an A,41'43'44 mostly preceded by a C.41 As a conse-
quence of the G to A transition at position 20210, a CA
dinucleotide (instead of GA) has been introduced at or near
the cleavage and polyadenylation site. However, in vitro
experiments so far do not support a hypothesis in which this
nucleotide Substitution will result in an increased efficiency
of the 3' end formation.41 Alternatively, it cannot be excluded
that the 20210 A allele is in linkage disequilibrium with
another sequence Variation (that escaped our analysis) that
is responsible for the elevated prothrombin levels.
Finally, our approach of sequencing a candidate gene for
thrombosis in a panel of probands from families with docu-
mented thrombophilia, followed by estimating the risk asso-
ciated with any observed sequence Variation in a population
based patient-control study, proved to be useful. This ap-
proach seems suitable for unraveling more unknown genetic
defects in other candidate genes for inherited thrombophilia.
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